2 results
Approved WMOWill not start
To test the hypothesis that CLL depend on their cognate BCR ligands for growth and/or survival and that lowering specific antigenic pressure decreases the activation status of the leukemia clone resulting in a decrease in tumor burden.
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.